The contribution of mitochondria to common disorders

Molecular Genetics and Metabolism

Volumn 80, Issue 1-2, 2003, Pages 11-26

  Enns, Gregory M ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Alzheimer disease; Cancer; Diabetes; Huntington disease; Mitochondria; Neurodegeneration; Parkinson disease; Succinate dehydrogenase

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; GLUTATHIONE ISOPROPYL ESTER; SELENIUM; UBIDECARENONE;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; BRAIN MITOCHONDRION; CANCER; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DNA DAMAGE; FRIEDREICH ATAXIA; GLUTATHIONE METABOLISM; HEARING LOSS; HUNTINGTON CHOREA; HYPERGLYCEMIA; INSULIN RELEASE; LIPID PEROXIDATION; MATERNAL DIABETES MELLITUS; MATURITY ONSET DIABETES MELLITUS; MELAS SYNDROME; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 0142121353     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymgme.2003.08.009     Document Type: Short Survey

References (157)

1. Wallace D.C. Mitochondrial defects in neurodegenerative disease. Ment. Retard. Dev. Disabil. Res. Rev. 7:2001;158-166.
2. Duchen M.R. Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signaling and cell death. J. Physiol. 516:1999;1-17.
3. Ischiropoulos H., Beckman J.S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J. Clin. Invest. 111:2003;163-169.
4. Chan C.B., De Leo D., Joseph J.W., McQuaid T.S., Ha X.F., Xu F., Tsushima R.G., Pennefather P.S., Salapatek A.M.F., Wheeler M.B. Increased uncoupling protein 2 levels in β-cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. Diabetes. 50:2001;1302-1310.
5. Zhang C.-Y., Baffy G., Perret P., Krauss S., Peroni O., Grujic D., Hagen T., Vidal-Pulg A.J., Boss O., Kim Y.-B., Zheng X.X., Wheeler M.B., Shulman G.I., Chan C.B., Lowell B.B. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, β-cell dysfunction, and type 2 diabetes. Cell. 105:2001;745-755.
6. Lamson D.L., Plaza S.M. Mitochondrial factors in the pathogenesis of diabetes: a hypothesis for treatment. Alt. Med. Rev. 7:2002;94-111.
7. Echtay K.S., Roussel D., St. Pierre J., Jekabsons M.B., Cadenas S., Stuart J.A., Harper J.A., Roebuck S.J., Morrison A., Pickering S., Clapham J.C., Brand M.D. Superoxide activates mitochondrial uncoupling proteins. Nature. 415:2002;96-99.
8. Wallace D.C. Mouse models for mitochondrial disease. Am. J. Med. Genet. (Semin. Med. Genet.). 106:2001;71-93.
9. Schulz J.B., Lindenau J., Seyfried J., Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 267:2000;4904-4911.
10. Orth M., Schapira A.H.V. Mitochondrial involvement in Parkinson's disease. Neurochem. Int. 40:2002;533-541.
11. Heales S.J.R., Bolaños J.P. Impairment of brain mitochondrial function by reactive nitrogen species: the role of glutathione in dictating susceptibility. Neurochem. Int. 40:2002;469-474.
12. Robertson R.P., Harmon J., Tran P.O., Tanaka Y., Takahashi H. Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 52:2003;581-587.
13. Cook H.R. The role of mitochondria and oxidative stress in neuronal damage after brief and prolonged seizures. Prog. Brain Res. 135:2002;187-196.
14. Sims N.R., Anderson M.F. Mitochondrial contributions to tissue damage in stroke. Neurochem. Int. 40:2002;511-526.
15. Schapira A.H.V. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim. Biophys. Acta. 1410:1999;159-170.
16. Corral-Debrinski M., Horton T., Lott M.T., Shoffner J.M., Beal M.F., Wallace D.C. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat. Genet. 2:1992;324-329.
17. Cortopassi G.A., Arnheim N. Detection of a specific mitochondrial DNA deletion in tissues of older humans. Nucleic Acids Res. 18:1990;6927-6933.
18. Cooper J.M., Mann V.M., Schapira A.H.V. Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: effect of ageing. J. Neurol. Sci. 113:1992;91-98.
19. Corral-Debrinski M., Shoffner J.M., Lott M.T., Wallace D.C. Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat. Res. 275:1992;169-180.
20. Michikawa Y., Mazzucchelli F., Gresolin N., Scarlato G., Attardi G. Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science. 286:1999;774-779.
21. Beckman K.B., Ames B.N. The free radical theory of aging matures. Physiol. Rev. 78:1998;547-581.
22. Richter C., Park J.W., Ames B.N. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. USA. 85:1988;6465-6467.
23. Muller-Hocker J., Seibel P., Scneiderbanger K., Kadenbach B. Different in situ hybridization patterns of mitochondrial DNA in cytochrome c oxidase-deficient extraocular muscle fibers in the elderly. Virchows Arch. A Pathol. Anat. Histopathol. 422:1993;7-15.
24. Lee C.K., Klopp R.G., Weindruch R., Prolla T.A. Gene expression profile of aging and its retardation by caloric restriction. Science. 285:1999;1390-1393.
25. Murdock D., Boone B.E., Esposito L., Wallace D.C. Up-regulation of nuclear and mitochondrial genes in the skeletal muscle of mice lacking the heart/muscle isoform of the adenine nucleotide translocator. J. Biol. Chem. 274:1999;14429-14433.
26. Bonilla E., Tanji K., Hirano M., Vu T.H., DiMauro S., Schon E.A. Mitochondrial involvement in Alzheimer's disease. Biochim. Biophys. Acta. 1410:1999;171-182.
27. Gibson G.E., Sheu K.-F.R., Blass J.P. Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural. Transm. 105:1998;855-870.
28. Yan S.D., Chen X., Schmidt A.M., Brett J., Godman G., Zou Y.S., Scott C.W., Caputo C., Frappier T., Smith M.A., Perry G., Yen S.H., Stern D. Glycated tau protein in Alzheimer's disease: a mechanism for induction of oxidative stress. Proc. Natl. Acad. Sci. USA. 91:1994;7787-7791.
29. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K., Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 91:1994;4766-4770.
30. Good P.F., Werner P., Hsu A., Olanow C.W., Perl D.P. Evidence for neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149:1996;21-28.
31. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer's (letter). Nature. 382:1996;120-121.
32. Griggs R.C., Askanas V., DiMauro S., Engel A.G., Karapati G., Mendell J.R., Rowland L.P. Inclusion body myositis and myopathies. Ann. Neurol. 38:1995;705-713.
33. Askanas V., McFerrin J., Baque S., Alvarez R.B., Sarkozi E., Engel W.K. Transfer of β-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc. Natl. Acad. Sci. USA. 93:1996;1314-1319.
34. Hensley K., Carney M.J., Mattson M.P., Aksenova M., Karris M., Floyd R.A., Butterfield D.A. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 91:1994;3270-3274.
35. Harris M.E., Hensley K., Butterfield D.A., Leedle R.A., Carney J.M. Direct evidence of oxidative injury produced by the Alzheimer β-amyloid protein (1-40) in cultured hippocampal neurons. Exp. Neurol. 131:1995;193-202.
36. Blass J.P. Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J. Neurosci. Res. 66:2001;851-856.
37. Chandrasekaran K., Hantanpää K., Brady D.R., Rapoport S.I. Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease. Exp. Neurol. 142:1996;80-88.
38. Ghosh S.S., Swerdlow R.H., Miller S.W., Sheeman B., Parker W.D. Jr., Davis R.E. Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. Ann. N. Y. Acad. Sci. 893:1999;176-191.
39. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36:1994;747-751.
40. Corral-Debrinski M., Horton T., Lott M.T., Shoffner J.M., McKee A.C., Beal M.F., Graham B.H., Wallace D.C. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics. 23:1994;471-476.
41. Shoffner J.M., Brown M.D., Torroni A., Lott M.T., Cabell M.F., Mirra S.S., Beal M.F., Yang C.-C., Gearing M., Salvo R., Watts R.L., Juncos J.L., Hansen L.A., Crain B.J., Fayad M., Reckord C.L., Wallace D.C. Mitochondrial DNA variants observed in Alzheimer's disease and Parkinson disease patients. Genomics. 17:1993;171-184.
42. A3243G mutation with Alzheimer's and Parkinson's diseases. Neuropathol. Appl. Neurobiol. 23:1997;315-321.
43. Mayr-Wohlfart U., Rodel G., Hennenberg A. Mitochondrial tRNA (Gln) and tRNA (Thr) gene variants in Parkinson's disease. Eur. J. Med. Res. 2:1997;111-113.
44. Brown M.D., Shoffner J.M., Kim Y.L., Jun A.S., Graham B.H., Cabell M.F., Gurley D.S., Wallace D.C. Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients. Am. J. Med. Genet. 61:1996;283-289.
45. Chinnery P.F., Taylor G.A., Howell N., Brown D.T., Parsons T.J., Turnbull D.M. Point mutations of the mtDNA control region in normal and neurodegenerative brains. Am. J. Hum. Genet. 68:2001;529-532.
46. Spillatini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. α-Synuclein in Lewy bodies. Nature. 388:1997;839-840.
47. Roman G.C., Zhang Z.-X., Ellenberg J.H. The neuroepidemiology of Parkinson's disease. Ellenberg J.H., Koller W.C., Langston J.W. Etiology of Parkinson's Disease. 1995;203-343 Marcel Dekker, New York.
48. Barroso N., Campos Y., Huertas R., Esteban J., Molina J.A., Alonso A., Gutierrez-Rivas E., Arenas J. Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson disease. Clin. Chem. 39:1993;667-669.
49. Gu M., Owen A.D., Toffa S.E.K., Cooper J.M., Dexter D.T., Jenner P., Marsden C.D., Schapira A.H.V. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J. Neurol. Sci. 158:1998;24-29.
50. Giasson B.I., Duda J.E., Murray I.V.J., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M.-Y. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science. 290:2000;985-989.
51. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73:1999;1127-1137.
52. Cohen G., Farooqui R., Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. USA. 94:1997;4890-4894.
53. + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim. Biophys. Acta. 1453:1999;49-62.
54. Cassarino D.S., Halvorsen E.M., Swerdlow R.H., Abramova N.N., Parker W.D. Jr., Sturgill T.W., Bennett J.P. Jr. Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-κB in cellular models of Parkinson's disease. J. Neurochem. 74:2000;1384-1392.
55. van der Walt J.M., Nicodemus K.K., Matin E.R., Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Haines J.L., Koeller W.C., Lyons K., Pahwa R., Stern B., Colcher A., Hiner B.C., Jankovic J., Ondo W.G., Allen F.H. Jr., Goetz C.G., Small G.W., Mastaglia F., Stajich J.M., McLaurin A.C., Middleton L.T., Scott B.L., Schmechel D.E., Pericak-Vance M.A., Vance J.M. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am. J. Hum. Genet. 72:2003;804-811.
56. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39:1996;385-389.
57. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., Schapira A.H.V. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45:1999;25-32.
58. Panov A.V., Gutekunst C.-A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5:2002;731-736.
59. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., Rahmani Z., Krisus A., McKenna-Yasek D., Cayabyab A., Gaston S.M., Berger R., Tanz R.E., Halperin J.J., Herzfeldt B., Van den Bergh R., Hung W.-Y., Bird T., Deng G., Mulder D.W., Smyth C., Laing N.G., Soriano E., Pericak-Vance M.A., Haines J., Rouleau G.A., Gusella J.S., Horvitz H.R., Brown R.H. Jr. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 362:1993;59-62.
60. Deng H.X., Hentati A., Tainer J.A., Iqbal Z., Acyabyab A., Hung W.Y., Getzoff E.D., Hu P., Herzfeldt B., Roos R.P., Warner C., Deng G., Soriano E., Smyth C., Parge H.E., Ahmed A., Roses A.D., Hallewell R.A., Pericak-Vance M.A., Siddique T. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science. 261:1993;1047-1051.
61. Selverstone Valentine J., Hart P.J. Misfolded CuZnSOD and amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 100:2003;3617-3622.
62. Shefner J.M., Reaume A.G., Flood D.G., Scott R.W., Kowall N.W., Ferrante R.J., Siwek D.F., Upton-Rice M., Brown R.H. Jr. Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy. Neurology. 53:1999;1239-1246.
63. Stadtman E.R., Berlett B.S. Reactive oxygen-mediated protein oxidation in aging and disease. Chem. Res. Toxicol. 10:1997;485-494.
64. Dal Canto M.C., Gurney M.E. Development of central nervous system pathology in a murine model of human amyotrophic lateral sclerosis. Am. J. Pathol. 145:1994;1271-1279.
65. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 14:1995;1105-1116.
66. Patel P.I., Isaya G. Friedreich ataxia: from GAA triplet-repeat expansion to frataxin deficiency. Am. J. Hum. Genet. 69:2001;15-24.
67. Lodi R., Cooper J.M., Bradley J.L., Manners D., Styles P., Taylor D.M., Schapira A.H.V. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl. Acad. Sci. USA. 96:1999;11492-11495.
68. Tan G., Chen L.-S., Lonnerdal B., Gellera C., Taroni F.A., Cortopassi G.A. Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Hum. Mol. Genet. 10:2001;2099-2107.
69. Piemonte F., Pastore A., Tozzi G., Tagliacozzi D., Santorelli F.M., Carrozzo R., Casali C., Damiano M., Federici G., Bertini E. Glutathione in blood of patients with Friedreich's ataxia. Eur. J. Clin. Invest. 31:2001;1007-1011.
70. Kaplan J. Spinocerebellar ataxias due to mitochondrial defects. Neurochem. Int. 40:2002;553-557.
71. Lombard J. Autism: a mitochondrial disorder? Med. Hypothesis. 50:1998;497-500.
72. Filano J.J., Goldenthal M.J., Rhodes C.H., Marin-Garcia J. Mitochondrial dysfunction in patients with hypotonia, epilepsy, autism, and developmental delay: HEADD syndrome. J. Child Neurol. 17:2002;435-439.
73. Bartsocas C.S., Leslie R.D.G. Genetics of diabetes mellitus. Am. J. Med. Genet. (Semin. Med. Genet.). 115:2002;1-3.
74. Ballinger S.W., Shoffner J.M., Hedaya E.V., Trounce I., Polak M.A., Koontz D.A., Wallace D.C. Maternally transmitted diabetes and deafness associated with a 10.4 kb mitochondrial DNA deletion. Nat. Genet. 1:1992;11-15.
75. Maechler P., Wollheim C.B. Mitochondrial function in normal and diabetic β-cells. Nature. 414:2001;807-812.
76. Leu (UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat. Genet. 1:1992;368-371.
77. Reardon W., Ross R.J.M., Sweeney M.G., Luxon L.M., Pembrey M.E., Harding A.E., Trembath R.C. Diabetes mellitus associated with a pathogenic point mutation in mitochondrial DNA. Lancet. 340:1992;1376-1379.
78. Maassen J.A., van Essen E., van den Ouweland M.M.W., Lemkes M.M.J.P. Molecular and clinical aspects of mitochondrial diabetes mellitus. Exp. Clin. Endocrinol. Diabetes. 109:2001;127-134.
79. Guillausseau P.-J., Massin P., Dubois-LaForgue D., Timsit J., Virally M., Gin H., Bertin E., Blickle J.-F., Bouhanick F., Cahen J., Caillat-Zucman S., Charpentier G., Chedin P., Derrien C., Ducluzeau P.-H., Grimaldi A., Guerci B., Kaloustian E., Murat A., Olivier F., Paques M., Paquis-Flucklinger V., Porokhov B., Samuel-Lageunesse J., Vialettes B. Maternally inherited diabetes and deafness: a multicenter study. Ann. Intern. Med. 134:2001;721-728.
80. Kadowaki T., Kadowaki H., Mori Y., Tobe K., Sakuta R., Suzuki Y., Tanabe Y., Sakura H., Awata T., Goto Y.-I., Hayakawa T., Matsuoka K., Kawamori R., Kamada T., Horai S., Nonaka I., Hagura R., Akanuma Y., Yazaki Y. A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N. Engl. J. Med. 330:1994;962-968.
81. Thomas A.W., Edwards A., Sherratt E.J., Majid A., Gagg J., Alcolado J.C. Molecular scanning of candidate mitochondrial tRNA genes in type 2 (non-insulin dependent) diabetes mellitus. J. Med. Genet. 33:1996;253-255.
82. Lee H.K., Song J.H., Shin C.S., Park D.J., Park K.S., Lee K.U., Koh C.-S. Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 42:1998;161-167.
83. Lee H.K. Evidence that the mitochondrial genome is the thrifty genome. Diabetes Res. Clin. Pract. 45:1999;127-135.
84. Park K.S., Lee K.-U., Song J.H., Choi C.S., Shin C.S., Park D.J., Kim S.K., Koh J.J., Lee H.K. Peripheral blood mitochondrial DNA content is inversely correlated with insulin secretion during hyperglycemic clamp studies in healthy young men. Diabetes Res. Clin. Pract. 52:2001;97-102.
85. Antonetti D.A., Reynet C., Kahn C.R. Increased expression of mitochondrial-encoded genes in skeletal muscle of humans with diabetes mellitus. J. Clin. Invest. 95:1995;1383-1388.
86. Serradas P., Giroix M.-H., Saulnier C., Gangnerau M.-N., Borg L.A.H., Welsh M., Portha G., Welsh N. Mitochondrial deoxyribonucleic acid content is specifically decreased in adult, but not fetal, pancreatic islets of the Goto-Kakizaki rat, a genetic model of noninsulin-dependent diabetes. Endocrinology. 136:1995;5623-5631.
87. Silva J.P., Köhler M., Graff C., Oldfors A., Magnuson M.A., Berggren P.-O., Larsson N.-G. Impaired insulin secretion and β-cell loss in tissue-specific knockout mice with mitochondrial diabetes. Nat. Genet. 26:2000;336-340.
88. Leinonen J., Lehtimäki T., Toyokuni S., Okada K., Tanaka T., Hial H., Ochi H., Laippala P., Rantalaiho V., Wirta O., Pasternack A., Alho H. New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus. FEBS Lett. 417:1997;150-152.
89. Hamilton M.L., Guo Z.M., Fuller C.D., van Remmen H., Ward W.F., Austad S.N., Troyer D.A., Thompson I., Richardson A. A reliable assessment of 8-oxo-2-deoxyguanosine levels in nuclear and mitochondrial DNA using the sodium iodide method to isolate DNA. Nucleic Acids Res. 29:2001;2117-2126.
90. Hinokio Y., Suzuki S., Hirai M., Chiba M., Hirai A., Toyota T. Oxidative DNA damage in diabetes mellitus: its association with diabetic complications. Diabetologia. 42:1999;995-998.
91. Suzuki S., Hinokio Y., Komatu K., Ohtomo M., Onoda M., Hirai S., Hirai M., Hirai A., Chiba M., Kasuga S., Adai H., Toyota T. Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. Diabetes Res. Clin. Pract. 45:1999;161-168.
92. Maechler P., Wollheim C.B. Mitochondrial signals in glucose-stimulated insulin secretion in the beta cell. J. Physiol. 529:2000;49-56.
93. Matschinsky F., Liang Y., Kesavan P., Wang L., Froguel P., Velho G., Cohen D., Permutt M.A., Tanizawa Y., Jetton T.L., Niswender K., Magnuson M.A. Glucokinase as pancreatic cell glucose sensor and diabetes gene. J. Clin. Invest. 92:1993;2092-2098.
94. Schuit F., de Vos A., Farfari S., Moens K., Pipeleers D., Brun T., Prentki M. Metabolic fate of glucose in purified islet cells. J. Biol. Chem. 272:1997;18572-18579.
95. Maassen J.A. Mitochondrial diabetes: pathophysiology, clinical presentation, and genetic analysis. Am. J. Med. Genet. (Semin. Med. Genet.). 115:2002;66-70.
96. 2+ and secretion. EMBO J. 9:1990;53-60.
97. Soejima A., Inoue K., Takai D., Kaneko M., Ishihara H., Oka Y., Hayashi J.-I. Mitochondrial DNA is required for regulation of glucose-stimulated insulin secretion in a mouse pancreatic beta cell line, MIN6. J. Biol. Chem. 271:1996;26194-26199.
98. 2+-independent insulin secretion from permeabilized RINm5F cells. J. Biol. Chem. 262:1987;5049-5056.
99. Prentki M., Vischer S., Glennon M.C., Regazzi R., Deeney J.T., Corkey B.E. Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion. J. Biol. Chem. 267:1992;5802-5810.
100. 2+- and GTP-dependent exocytosis in mouse pancreatic β-cells involves both common and distinct steps. J. Physiol. 496:1996;255-264.
101. Antinozzi P.A., Segall L., Prentki M., McGarry J.D., Newgard C.B. Molecular or pharmacologic perturbation of the link between glucose and lipid metabolism is without effect on glucose-stimulated insulin secretion. J. Biol. Chem. 273:1998;16146-16154.
102. Maechler P., Wollheim C.B. Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. Nature. 402:1999;685-689.
103. MacDonald M.J., Fahien L.A. Glutamate is not a messenger in insulin secretion. J. Biol. Chem. 275:2000;34025-34027.
104. Stanley C.A., Lieu Y.K., Hsu B.Y., Burlina A.B., Greenberg C.R., Hopwood N.J., Perlman K., Rich B.H., Zammarchi E., Poncz M. Hyperinsulinism and hyperammonemia in infants with regulatory mutations in the glutamate dehydrogenase gene. N. Engl. J. Med. 338:1998;1352-1357.
105. Maassen J.A. Mitochondrial diabetes, diabetes and the thiamine-responsive megaloblastic anaemia syndrome and MODY2. Panminerva Med. 44:2002;295-300.
106. Neufeld E.J., Fleming J.C., Tartaglini E., Steinkamp M.P. Thiamine-responsive megaloblastic anemia syndrome: a disorder of high-affinity thiamine transport. Blood Cells Mol. Dis. 27:2001;135-138.
107. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 414:2001;813-820.
108. Du X.-L., Edelstein D., Rossetti L., Fantus I.G., Goldberg H., Ziyadeh F., Wu J., Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. USA. 97:2000;12222-12226.
109. Maritim A.C., Sanders R.A., Watkins III J.B. Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17:2003;24-38.
110. Roduit R., Morin J., Massé F., Segall L., Roche E., Newgard C.B., Assimacopoulos-Jeannet F., Prentki M. Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-α gene in the pancreatic β-cell. J. Biol. Chem. 275:2000;35799-35806.
111. Frayling T.M., Evans J.C., Bulman M.P., Pearson E., Allen L., Owen K., Bingham C., Hannemann M., Shepherd M., Ellard S., Hattersley A.T. β-Cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes. 50(Suppl. 1):2001;S94-S100.
112. Wang H., Antinozzi P.A., Hagenfeldt K.A., Maechler P., Wollheim C.B. Molecular targets of a human HNF1α mutation responsible for pancreatic β-cell dysfunction. EMBO J. 19:2000;4257-4264.
113. Weigert C., Friess U., Brodbeck K., Haring H.U., Schleicher E.D. Glutamine:fructose-6-phosphate aminotransferase enzyme activity is necessary for the induction of TGF-beta1 and fibronectin expression in mesangial cells. Diabetologia. 46:2003;852-855.
114. Kolm-Litty V., Sauer U., Nerlich A., Lehmann R., Schleicher E.D. High glucose-induced transforming growth factor β1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest. 101:1998;160-169.
115. Du X.L., Edelstein D., Dimmeler S., Ju Q., Sui C., Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 108:2001;1341-1348.
116. Williamson J.R., Chang K., Frangos M., Hasan K.S., Ido Y., Kawamura T., Nyengaard J.R., van den Enden M., Kilo C., Tilton R.G. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 42:1993;801-813.
117. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., Shoelson S.E. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 293:2001;1673-1677.
118. 2. J. Clin. Invest. 96:1995;733-740.
119. Craven P.A., Studer R.K., DeRubertis F.R. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response. J. Clin. Invest. 93:1994;311-320.
120. Kuboki K., Jiang Z.Y., Takahara N., Ha S.W., Igarashi M., Yamauchi T., Feener E.P., Herbert T.P., Rhodes C.J., King G.L. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 101:2000;676-681.
121. Craven P.A., Studer R.K., Felder J., Phillips S., DeRoberts F.R. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes. 46:1997;671-681.
122. Bandy B., Davison A.J. Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging? Free Radic. Biol. Med. 8:1990;523-539.
123. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C., Myssiorek D., Bosch A., van der Mey A., Raschner P.E.M., Rubinstein W.S., Myers E.N., Richard III C.W., Cornelisse C.J., Devilee P., Devlin B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 287:2000;848-851.
124. Astuti D., Latif F., Dallol A., Dahia P.L.M., Douglas F., George E., Sköldberg F., Husebye E.S., Eng C., Maher E.R. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 69:2001;49-54.
125. Gimenez-Roqueplo A.-P., Favier J., Rustin P., JMourad J.-J., Plouin P.-F., Corvol P., Rötig A., Jeunemaitre X. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet. 69:2001;1186-1197.
126. Niemann S., Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet. 26:2000;268-270.
127. Neumann H.P.H., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G., Schipper J., Klisch J., Altehoefer C., Zerres K., Januszewicz A., Eng C. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346:2002;1459-1466.
128. Tomlinson I.P.M., Alam N.A., Rowan A.J., Barclay E., Jaegger E.E.M., Kelsell D., Leigh I., Gorman P., Lamlum H., Rahman S., Roylance R.R., Olpin S., Beven S., Barker K., Hearle N., Houlston R.S., Kiuru M., Lehtonen R., Karhu A., Vikki A., Laiho P., Eklund C., Vierimaa O., Aittomäki K., Hietala M., Sistonen P., Paetau A., Salovaara R., Herva R., Launonen V., Aaltonen L.A. Multiple Leiomyoma Consortium. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30:2002;406-410.
129. Eng C., Kiuru M., Fernandez M.J., Aaltonen L.A. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat. Rev. Cancer. 3:2003;193-202.
130. Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic. Biol. Med. 6:1989;593-597.
131. Ferrari G., Yan C.Y.I., Greene L.A. N-acetylcysteine (D- and L-stereoisomers) prevent apoptotic death of neuronal cells. J. Neurosci. 15:1995;2857-2866.
132. Mayer M., Noble M. N-acetylcysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc. Natl. Acad. Sci. USA. 91:1994;7496-7500.
133. Yan C.Y.I., Greene L.A. Prevention of PC12 cell death by N-acetylcysteine requires activation of the Ras pathway. J. Neurosci. 18:1998;4042-4049.
134. Yamamoto M., Sakamoto N., Iwai A., Yatsugi S., Hidaka K., Noguchi K., Yuasa T. Protective actions of YM737, a new glutathione analog, against cerebral ischemia in rats. Res. Commun. Chem. Pathol. Pharmacol. 81:1993;221-232.
135. Henderson J.T., Javaheri M., Kopko S., Roder J.C. Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine. J. Neurosci. 16:1996;7574-7582.
136. Banaclocha M.M. Therapeutic potential of N-acetylcysteine in age-related mitochondrial neurodegenerative diseases. Med. Hypothesis. 56:2001;472-477.
137. Cedkowicz M.E., Sexton P.M., Ellis T., Hayden D.L., Gwilt P.R., Whalen J., Brown H. Jr. The pharmacokinetics and pharmacodynamics of procysteine in amyotrophic lateral sclerosis. Neurology. 52:1999;1492-1494.
138. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes. 19:1996;257-267.
139. Dinçer Y., Akçay T., Alademir Z., İlkova H. Assessment of DNA base oxidation and glutathione level in patients with type 2 diabetes. Mutat. Res. 505:2002;75-81.
140. Dincer Y., Akcay T., Alademir Z., Ilkova H. Effect of oxidative stress on glutathione pathway in red blood cells from patients with insulin-dependent diabetes. Metabolism. 51:2002;1360-1362.
141. Kim S.K., Woodcroft K.J., Novak R.F. Insulin and glucagons regulation of glutathione. S -transferase expression in primary cultured rat hepatocytes J. Pharmacol. Exp. Ther. 305:2003;353-361.
142. Yilmaz Ö., Özkan Y., Yildirim M., Özürk A.I., Erşan Y. Effects of alpha lipoic acid, ascorbic acid-6-palmitate, and fish oil on the glutathione, malonaldehyde, and fatty acids levels in erythrocytes of streptozotocin induced diabetic male rats. J. Cell Biochem. 86:2002;530-539.
143. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kandea Y., Yorek M.A., Oates P.J., Hammes H.-P., Giardino I., Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 404:2000;787-790.
144. Lortz S., Tiedge M. Sequential inactivation of reactive oxygen species by combined overexpression of SOD isoforms and catalase in insulin-producing cells. Free Radic. Biol. Med. 34:2003;683-688.
145. Park L., Raman K.G., Lee K.J., Lu Y., Ferran L.J. Jr., Chow W.S., Stern D., Schmidt A.M. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4:1998;1025-1031.
146. Kashiba M., Oka J., Ichikawa R., Kasahara E., Inayama T., Kageyama A., Kageyama H., Osaka T., Umegaki K., Matsumoto A., Ishikawa T., Nishikimi M., Inoue M., Inoue S. Impaired ascorbic acid metabolism in streptozotocin-induced diabetic rats. Free Radic. Biol. Med. 33:2002;1221-1230.
147. Ting H.H., Timimi F.K., Boles K.S., Creager S.J., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 97:1996;22-28.
148. Gerstein H.C., Yusuf S., Mann J.F.E., Hoogwerf B., Zinman B., Held C., Fisher M., Wolffenbuttel B., Bosch J., Richardson L., Pogue J., Halle J.-P. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 355:2000;253-259.
149. Ganz M.B., Seftel A. Glucose-induced changes in protein kinase C and nitric oxide are prevented by vitamin E. Am. J. Physiol. Endocrinol. Metab. 278:2000;E146-E152.
150. Kowluru R.A., Tang J., Kern T.S. Abnormalities of retinal metabolism in diabetes and experimental galactosemia: VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes. 50:2001;1938-1942.
151. Silvestre-Aillaud P., BenDahan D., Paquis-Fluckinger V., Pouget J.,
152. Suzuki Y., Kadowaki H., Atsumi Y., Hosokawa K., Katagiri H., Kadowaki T., Oka Y., Uyama K., Mokubo A., Asahina T., Murata C., Matsuoka K. A case of diabetic amyotrophy associated with 3243 mitochondrial tRNA(leu;UUR) mutation and successful therapy with coenzyme Q10. Endocrine J. 42:1995;141-145.
153. 10 treatment. Mol. Aspects Med. 18:1997;s181-s188.
154. 10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A-G) mutation. Diabetologia. 41:1998;584-588.
155. 10 in a patient with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome and diabetes mellitus. Eur. Neurol. 43:2000;54-55.
156. Cameron E., Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. USA. 73:1976;3685-3689.
157. Moertel C.G., Fleming T.R., Creagan E.T., Rubin J., O'Connell M.J., Ames M.M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. N. Engl. J. Med. 312:1985;137-141.